The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation
Abstract
After bone marrow transplantation (BMT) using T-cell–depleted marrow from an unrelated donor or HLA-mismatched related donor, the risk of developing lymphoproliferative disease associated with the Epstein-Barr virus (EBV) ranges from 1% to 25%. We have shown that administration of donor-derived EBV-specific cytotoxic T lymphocytes (CTL) is effective prophylaxis and treatment for this complication, and we routinely generate CTL for high-risk patients. However, EBV lymphoma can occur in recipients of matched-sibling transplants for whom CTL are unavailable or in patients for whom CTL administration is contraindicated. We report on 3 such patients, who were successfully and safely treated with rituximab, a CD20 monoclonal antibody. The patients remain disease free 7, 8, and 9 months, respectively, after therapy. We conclude that CD20 antibody may be a useful alternative treatment strategy in patients with EBV lymphoma after BMT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2188 · Cited by 1,733
Rooney, C. M., Ng, C. Y. C., Loftin, S., Smith, C. A., Li, C., Krance, R. A., Brenner, M. K., Heslop, H. E., Rooney, C. M., Brenner, M. K., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91150-2 · Cited by 1,173
Self-citationRooney, C. M., Smith, C. A., Ng, C. Y. C., Loftin, S. K., Sixbey, J. W., Gan, Y., Srivastava, D.-K., Bowman, L. C., Krance, R. A., Brenner, M. K., et al. (1998) · Blood · doi:10.1182/blood.v92.5.1549 · Cited by 1,135
Self-citationPapadopoulos, E. B., Ladanyi, M., Emanuel, D., Mackinnon, S., Boulad, F., Carabasi, M. H., Castro-Malaspina, H., Childs, B. H., Gillio, A. P., Small, T. N., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199404283301703 · Cited by 1,043
Heslop, H. E., Ng, C. Y. C., Li, C., Smith, C. A., Loftin, S. K., Krance, R. A., Brenner, M. K., & Rooney, C. M. (1996) · Nature Medicine · doi:10.1038/nm0596-551 · Cited by 821
Self-citationFischer, A., Blanche, S., Le Bidois, J., Bordigoni, P., Garnier, J. L., Niaudet, P., Morinet, F., Le Deist, F., Fischer, A.-M., Griscelli, C., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199105233242102 · Cited by 343
Davis, T. A., Czerwinski, D. K., & Levy, R. (1999) · PubMed · Cited by 267
Use of rituximab, the new FDA-approved antibody
Leget, G. A., & Czuczman, M. S. (1998) · Current Opinion in Oncology · doi:10.1097/00001622-199811000-00012 · Cited by 251
Donor T Cells to Treat EBV-Associated Lymphoma
(1994) · New England Journal of Medicine · doi:10.1056/nejm199409083311017 · Cited by 250
Lucas, K. G., Burton, R. L., Zimmerman, S. E., Wang, J., Cornetta, K. G., Robertson, K. A., Lee, C. H., & Emanuel, D. J. (1998) · Blood · doi:10.1182/blood.v91.10.3654 · Cited by 226
Cited by
Heslop, H. E., Slobod, K. S., Pule, M. A., Hale, G. A., Rousseau, A., Smith, C. A., Bollard, C. M., Liu, H., Wu, M.-F., Rochester, R. J., et al. (2010) · Blood · doi:10.1182/blood-2009-08-239186 · Cited by 780
Self-citationPost-Transplant Lymphoproliferative Disorders
Gottschalk, S., Rooney, C. M., & Heslop, H. E. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104727 · Cited by 489
Self-citationRituximab for steroid-refractory chronic graft-versus-host disease
Cutler, C., Miklos, D., Kim, H. T., Treister, N., Woo, S.-B., Bienfang, D., Klickstein, L. B., Levin, J., Miller, K., Reynolds, C., et al. (2006) · Blood · doi:10.1182/blood-2006-01-0233 · Cited by 452
Ho, V. T., & Soiffer, R. J. (2001) · Blood · doi:10.1182/blood.v98.12.3192 · Cited by 426
Graft-versus-leukemia reactions in allogeneic chimeras
Kolb, H.-J., Schmid, C., Barrett, A. J., & Schendel, D. J. (2004) · Blood · doi:10.1182/blood-2003-02-0342 · Cited by 397
Metadata
- Authors
- Kuehnle, I., Huls, M. H., Liu, Z., Semmelmann, M., Krance, R. A., Brenner, M. K., Rooney, C. M., & Heslop, H. E.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2000-02-15
- Volume
- 95
- Issue
- 4
- Pages
- 1502-1505
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1266345587
- Cited by
- 274
- References
- 14
- FWCI
- 15.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. https://app.cochat.ai/papers/10.1182/blood.v95.4.1502.004k40_1502_1505
- The paper
- Kuehnle, I., Huls, M. H., Liu, Z., Semmelmann, M., Krance, R. A., Brenner, M. K., Rooney, C. M., & Heslop, H. E. (2000). CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. https://doi.org/10.1182/blood.v95.4.1502.004k40_1502_1505
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.